ES2108642A1 - Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. - Google Patents

Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Info

Publication number
ES2108642A1
ES2108642A1 ES09501603A ES9501603A ES2108642A1 ES 2108642 A1 ES2108642 A1 ES 2108642A1 ES 09501603 A ES09501603 A ES 09501603A ES 9501603 A ES9501603 A ES 9501603A ES 2108642 A1 ES2108642 A1 ES 2108642A1
Authority
ES
Spain
Prior art keywords
tungsten
pharmaceutical compositions
diabetes mellitus
compositions
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09501603A
Other languages
English (en)
Other versions
ES2108642B1 (es
Inventor
Cirera Joan Josep Guinovart
Lluis Albert Barbera
Gil Joan Enric Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Hispania SL
Original Assignee
Quimica Farmaceutica Bayer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/504,020 priority Critical patent/US5595763A/en
Application filed by Quimica Farmaceutica Bayer SA filed Critical Quimica Farmaceutica Bayer SA
Priority to ES9501603A priority patent/ES2108642B1/es
Priority to EP96500106A priority patent/EP0755681A1/en
Priority to JP19733096A priority patent/JPH09118624A/ja
Publication of ES2108642A1 publication Critical patent/ES2108642A1/es
Application granted granted Critical
Publication of ES2108642B1 publication Critical patent/ES2108642B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIONES DE TUNGSTENO (VI) PARA EL TRATAMIENTO ORAL DE LA DIABETES MELLITUS. COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE TUNGSTENO (VI), PREFERIBLEMENTE DE TUNGSTATO O DE UN POLITUNGSTATO, Y MAS PREFERIBLEMENTE DE TUNGSTATO SODICO. USO DE LOS COMPUESTOS DE TUNGSTENO (VI) PARA LA PREPARACION DE UN MEDICAMENTO ORAL PARA BAJAR LA CONCENTRACION SANGUINEA DE AZUCAR EN UN SER HUMANO QUE SUFRE DE DIABETES MELLITUS DE TIPO 1 (DMID) O DE TIPO 2 (DMNID). COMPARADAS CON LAS CONOCIDAS COMPOSICIONES DE VANADIO QUE SON AGENTES MIMETIZADORES DE LA INSULINA, LAS COMPOSICIONES FARMACEUTICAS DE LA PRESENTE INVENCION TIENEN LA VENTAJA DE PRESENTAR UNA TOXICIDAD ORAL MUCHO MENOR, TANTO A CORTO COMO A LARGO PLAZO. COMPARADAS CON LA INSULINA, LAS COMPOSICIONES FARMACEUTICAS DE LA INVENCION NO PRESENTAN EL EFECTO ADVERSO DE INDUCIR HIPOGLICEMIA CUANDO SE ADMINISTRAN EN EXCESO. SON UTILES EN TERAPEUTICA HUMANA.
ES9501603A 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. Expired - Fee Related ES2108642B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/504,020 US5595763A (en) 1995-07-19 1995-07-19 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
EP96500106A EP0755681A1 (en) 1995-07-19 1996-07-25 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
JP19733096A JPH09118624A (ja) 1995-07-26 1996-07-26 真性糖尿病の経口処置用タングステン（ｖｉ）組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Publications (2)

Publication Number Publication Date
ES2108642A1 true ES2108642A1 (es) 1997-12-16
ES2108642B1 ES2108642B1 (es) 1998-08-16

Family

ID=8291317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9501603A Expired - Fee Related ES2108642B1 (es) 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Country Status (2)

Country Link
JP (1) JPH09118624A (es)
ES (1) ES2108642B1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098435A1 (es) * 2001-05-16 2002-12-12 Química Farmacéutica Bayer, S.A. Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos
WO2007014970A1 (es) * 2005-07-29 2007-02-08 Universidad De Barcelona Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
WO2014096498A1 (es) * 2012-12-21 2014-06-26 Universitat De Barcelona Sales de tungstato como agentes antiplaquetarios
ES2478790A1 (es) * 2013-01-22 2014-07-22 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES2551828A1 (es) * 2014-05-21 2015-11-23 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
WO2016012632A1 (es) * 2014-07-21 2016-01-28 Oxolife S.L Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025916A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 入浴水
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025916A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 入浴水
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARBERA, A. et al. Insulin-like actions of tungstate in diabetic rats. The Journal of Biological Chemistry, 1994, Vol. 269, n‘ 31, pßginas 20047-20053 *
BASE DE DATOS WPIL en Questel, semana 8512, Londres, Derwent Publications Ltd., AN 85-071655 & JP 60025916 A (TANAKA, S) 08.02.85 * Resumen * *
BASE DE DATOS WPIL en Questel, semana 8512, Londres, Derwent Publications Ltd., AN 85-071661 & JP 60025928 A (TANAKA, S) 08.02.85 * Resumen * *
GOTO, Y. et al. Synergism in insulin-like effects of molybdate plus H2O2 or tungstate plus H2O2 on glucose transport by isolated rat adipocytes. Biochemical Pharmacology, 1992, Vol. 44, N‘ 1, páginas 174-177 * Resumen; página 174, columna 1, líneas 1-5 * *
MATSUMOTO, J. Vanadate, Molybdate and tungstate for orthomolecular Medicine. Medical Hypotheses, 1994, Vol. 43, pßginas 177-182 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098435A1 (es) * 2001-05-16 2002-12-12 Química Farmacéutica Bayer, S.A. Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos
ES2187276A1 (es) * 2001-05-16 2003-05-16 Quimica Farm Bayer Sa Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
US7122209B2 (en) 2001-05-16 2006-10-17 Quimica Farmaceutica Bayer S.A. Oral compositions for the treatment of non-diabetic obese mammals, including humans
EP1972342A4 (en) * 2005-07-29 2011-01-12 Univ Barcelona PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA
EP1972342A1 (en) * 2005-07-29 2008-09-24 Universidad De Barcelona Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
WO2007014970A1 (es) * 2005-07-29 2007-02-08 Universidad De Barcelona Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
WO2014096498A1 (es) * 2012-12-21 2014-06-26 Universitat De Barcelona Sales de tungstato como agentes antiplaquetarios
ES2478790A1 (es) * 2013-01-22 2014-07-22 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
US9675638B2 (en) 2013-01-22 2017-06-13 Oxolife, S.L. Use of tungsten (VI) salts for the treatment of female infertility in non-diabetic mammals
ES2551828A1 (es) * 2014-05-21 2015-11-23 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
WO2016012632A1 (es) * 2014-07-21 2016-01-28 Oxolife S.L Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
US10376540B2 (en) 2014-07-21 2019-08-13 Oxolike, S.L. Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques

Also Published As

Publication number Publication date
ES2108642B1 (es) 1998-08-16
JPH09118624A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
Whitehouse et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
HUP0300642A2 (hu) Antidiabetikus készítmény és alkalmazása
FI883423A (fi) Foerfarande foer framstaellning av terapeutisk anvaendbara piperazinylderivat av puriner.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
US20030040478A1 (en) Chemotherapy treatment
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
SG149814A1 (en) Compositions and methods for treating diabetes
BG105531A (en) Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
HUP0302550A2 (hu) Glükopiranozil-oxi-pirazol-származékok és gyógyászatban való alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
KR890012666A (ko) 신장 질환의 치료방법
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
CA2297834C (en) Chromium/biotin treatment of type ii diabetes
FR2653020A1 (fr) Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
IL92358A0 (en) Diaryl compounds,their preparation and pharmaceutical compositions containing them
AU5314694A (en) New agents for diagnosis of vascular diseases
HUP0003629A2 (hu) Szinergista gyógyszerkészítmény diabetes kezelésére amely dioxo-tiazolidint, inzulin secretagogot és diguanidint tartalmaz
ES2108642A1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
Kan et al. Haemoglobin Constant Spring synthesis in red cell precursors
US20020128235A1 (en) Prevention and/or treatment of diabetes mellitus by pharmacologically inhibiting pancreatic beta-cell O-linked protein glycosylation and/or pancreatic beta-cell p135 O-glycosylation
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: QUIMICA FARMACEUTICA BAYER, S.A.

FD1A Patent lapsed

Effective date: 20100528